Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia.
Desai A, Benner L, Wu R, Gertsik L, Maruff P, Light GA, Uz T, Marek GJ, Zhu T. Desai A, et al. Among authors: uz t. Neuropsychopharmacology. 2021 May;46(6):1145-1151. doi: 10.1038/s41386-020-00908-0. Epub 2020 Nov 17. Neuropsychopharmacology. 2021. PMID: 33203954 Free PMC article. Clinical Trial.
Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study.
Ito M, Tauscher-Wisniewski S, Smulders RA, Wojtkowski T, Yamada A, Koibuchi A, Uz T, Marek GJ, Goldwater RD. Ito M, et al. Among authors: uz t. Muscle Nerve. 2022 Jan;65(1):110-120. doi: 10.1002/mus.27436. Epub 2021 Oct 28. Muscle Nerve. 2022. PMID: 34642949 Free PMC article. Clinical Trial.
Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [11C]PHNO PET.
Rabiner EA, Uz T, Mansur A, Brown T, Chen G, Wu J, Atienza J, Schwarz AJ, Yin W, Lewis Y, Searle GE, Dennison JMTJ, Passchier J, Gunn RN, Tauscher J. Rabiner EA, et al. Among authors: uz t. Neuropsychopharmacology. 2022 Jun;47(7):1405-1412. doi: 10.1038/s41386-021-01204-1. Epub 2021 Oct 21. Neuropsychopharmacology. 2022. PMID: 34675381 Free PMC article.
An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
Gilleen J, Farah Y, Davison C, Kerins S, Valdearenas L, Uz T, Lahu G, Tsai M, Ogrinc F, Reichenberg A, Williams SC, Mehta MA, Shergill SS. Gilleen J, et al. Among authors: uz t. Psychopharmacology (Berl). 2021 May;238(5):1279-1289. doi: 10.1007/s00213-018-5134-y. Epub 2018 Dec 8. Psychopharmacology (Berl). 2021. PMID: 30536081 Free PMC article. Clinical Trial.
81 results